Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421017 · ClinicalTrials.gov registry record · Phase 1
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01421017 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 31 participants.
The verdict
NCT01421017, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases from breast cancer in the second part (Phase II). Currently this trial is in its Phase II part.
Interventions
- DRUG Cyclophosphamide
- RADIATION Radiation
- DRUG Imiquimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-08-19 |
| Est. Completion | 2016-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421017
The ClinicalTrials.gov registry entry for NCT01421017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT01421017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01421017 about?
NCT01421017 is a clinical study titled "Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases". This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and radiotherapy (RT) in patients with skin metastases from breast cancer in the second part (Phase II). Currently this trial i...
What is the current status of trial NCT01421017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2011-08-19. Estimated completion is 2016-08-06.
What interventions are being tested in trial NCT01421017?
The interventions under investigation include: Cyclophosphamide (DRUG), Radiation (RADIATION), Imiquimod (DRUG).
Who is sponsoring clinical trial NCT01421017?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.